We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

86 hedge funds and large institutions have $1.12B invested in Loxo Oncology, Inc in 2017 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 43 increasing their positions, 17 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 17

66% more capital invested

Capital invested by funds: $677M → $1.12B (+$447M)

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

0% more funds holding

Funds holding: 8686 (0)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
86
Holders Change
Holders Change %
0%
% of All Funds
2.14%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
18
Increased
43
Reduced
17
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SCA
51
Secor Capital Advisors
New York
$1.33M +$1.31M +31,689 New
Morgan Stanley
52
Morgan Stanley
New York
$1.32M -$537K -13,028 -29%
SO
53
STRS Ohio
Ohio
$1.21M -$238K -5,783 -17%
Swiss National Bank
54
Swiss National Bank
Switzerland
$1.21M +$412K +10,000 +53%
TA
55
Teachers Advisors
New York
$1.19M +$248K +6,023 +27%
NFA
56
Nationwide Fund Advisors
Ohio
$1.15M +$273K +6,632 +32%
Citadel Advisors
57
Citadel Advisors
Florida
$1.06M +$1.04M +25,257 New
AR
58
Advisory Research
Illinois
$1.03M +$1.01M +24,419 New
AA
59
ALPS Advisors
Colorado
$925K +$47.3K +1,148 +6%
D.E. Shaw & Co
60
D.E. Shaw & Co
New York
$818K -$1.14M -27,742 -59%
DekaBank Deutsche Girozentrale
61
DekaBank Deutsche Girozentrale
Germany
$803K +$379K +9,200 +92%
RhumbLine Advisers
62
RhumbLine Advisers
Massachusetts
$731K +$128K +3,118 +22%
New York State Common Retirement Fund
63
New York State Common Retirement Fund
New York
$661K +$41.2K +1,001 +7%
Wells Fargo
64
Wells Fargo
California
$653K +$160K +3,875 +33%
ProShare Advisors
65
ProShare Advisors
Maryland
$565K -$125K -3,038 -18%
Citigroup
66
Citigroup
New York
$501K +$55.4K +1,344 +13%
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$473K +$63.7K +1,546 +16%
MLICM
68
Metropolitan Life Insurance Company (MetLife)
New York
$444K
VEA
69
Virtus ETF Advisers
New York
$438K +$41.1K +997 +11%
AIG
70
American International Group
New York
$410K +$85.7K +2,081 +27%
Bank of America
71
Bank of America
North Carolina
$344K +$209K +5,063 +163%
AQR Capital Management
72
AQR Capital Management
Connecticut
$342K -$144K -3,498 -30%
T. Rowe Price Associates
73
T. Rowe Price Associates
Maryland
$267K +$412 +10 +0.2%
VOYA Investment Management
74
VOYA Investment Management
Georgia
$258K +$252K +6,123 New
Barclays
75
Barclays
United Kingdom
$207K +$17.7K +429 +10%

LOXO Hedge Fund Activity: Q1 2017 in Review

86 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q1 2017, worth a combined $1.12B — up 66% from $677M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new LOXO positions and 13 closed out — a net gain of 5 holders — while 43 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $54.7M. The largest seller was Eventide Asset Management, cutting an estimated $6.63M.

  • 86 institutional investors held Loxo Oncology, Inc (LOXO) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $1.12B of Loxo Oncology, Inc stock for Q1 2017, up 66% quarter-over-quarter.
  • 18 funds opened new Loxo Oncology, Inc positions in Q1 2017 and 13 closed out, a net change of +5 holders.
  • The largest Loxo Oncology, Inc buyer in Q1 2017 was BlackRock, an estimated $54.7M added.
  • The largest Loxo Oncology, Inc seller in Q1 2017 was Eventide Asset Management, an estimated $6.63M sold.

Based on aggregated 13F filings for Q1 2017.